Avidity Biosciences
IPO News: Avidity Biosciences File $100mm IPO
Avidity Biosciences

Avidity Biosciences


Size:  $100mm

Bookrunners:  Cowen | SVB Leerink | Credit Suisse | Wells Fargo

Major Holders:  RTW Investments | Cormorant | Eli Lilly & Co. | ALETHEA Capital Management | EcoR1 Capital

Description:  Avidity is pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.


Reference Link:  S-1